Product Code: ETC6189472 | Publication Date: Sep 2024 | Updated Date: Aug 2025 | Product Type: Market Research Report | |
Publisher: 6Wresearch | Author: Shubham Padhi | No. of Pages: 75 | No. of Figures: 35 | No. of Tables: 20 |
Within the broader pruritus care landscape, the Pruritus Drug Market in Australia is evolving with pharmaceutical innovations aiming to address various underlying causesranging from dermatological disorders to kidney or liver diseases. While conventional antihistamines and corticosteroids dominate, the growing pipeline of novel drugs, including JAK inhibitors and neurokinin-1 receptor antagonists, is generating interest. However, high costs, delayed drug approvals, and reimbursement issues may pose hurdles to market entry and expansion.
Closely linked to the broader pruritus market, the pruritus drug segment in Australia is trending toward innovation in drug development. The focus is on identifying non-histaminergic pathways that contribute to chronic itch, leading to the development of novel therapies such as kappa-opioid receptor agonists and neurokinin receptor antagonists. Topical treatments with fewer systemic side effects are also gaining popularity. Additionally, there`s an increasing interest in combination therapies and personalized medicine to improve patient outcomes.
The Pruritus Drug Market in Australia faces several challenges, including the difficulty in developing drugs that can effectively address the wide array of causes of pruritus. Additionally, the market must contend with high regulatory scrutiny for new drug approvals, which often results in long development timelines and expensive clinical trials. There is also a lack of targeted therapies, with many treatments offering only temporary relief or having limited effectiveness for certain causes of pruritus. The high cost of innovative treatments and their availability only through prescription further limits access for many patients.
The pruritus drug market in Australia is gaining momentum due to the introduction of novel molecules and increased prescriptions for antihistamines and corticosteroids. Opportunities exist in bringing advanced, targeted therapies to the Australia Therapeutic Goods Administration (TGA) for approval and marketing. Companies investing in rare disease portfolios and expanding dermatological pipelines may find attractive long-term returns here.
The regulation of pruritus drugs falls under the TGA, which evaluates drug safety, efficacy, and quality. Drugs addressing systemic and dermatologic pruritus are included in PBS listings when deemed cost-effective, aiding widespread patient access. The government also monitors side effects and issues drug safety updates as part of post-market surveillance.
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 Australia Pruritus Drug Market Overview |
3.1 Australia Country Macro Economic Indicators |
3.2 Australia Pruritus Drug Market Revenues & Volume, 2021 & 2031F |
3.3 Australia Pruritus Drug Market - Industry Life Cycle |
3.4 Australia Pruritus Drug Market - Porter's Five Forces |
3.5 Australia Pruritus Drug Market Revenues & Volume Share, By Types, 2021 & 2031F |
3.6 Australia Pruritus Drug Market Revenues & Volume Share, By Drugs, 2021 & 2031F |
3.7 Australia Pruritus Drug Market Revenues & Volume Share, By Route of Administration, 2021 & 2031F |
3.8 Australia Pruritus Drug Market Revenues & Volume Share, By End Users, 2021 & 2031F |
3.9 Australia Pruritus Drug Market Revenues & Volume Share, By Distribution Channel, 2021 & 2031F |
4 Australia Pruritus Drug Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.2.1 Increasing prevalence of pruritus conditions in Australia |
4.2.2 Growing awareness about available treatment options for pruritus |
4.2.3 Technological advancements in drug development for pruritus |
4.3 Market Restraints |
4.3.1 Stringent regulatory requirements for drug approval |
4.3.2 High cost associated with research and development of pruritus drugs |
5 Australia Pruritus Drug Market Trends |
6 Australia Pruritus Drug Market, By Types |
6.1 Australia Pruritus Drug Market, By Types |
6.1.1 Overview and Analysis |
6.1.2 Australia Pruritus Drug Market Revenues & Volume, By Types, 2021- 2031F |
6.1.3 Australia Pruritus Drug Market Revenues & Volume, By Chronic Kidney Disease associated Pruritus, 2021- 2031F |
6.1.4 Australia Pruritus Drug Market Revenues & Volume, By Chronic Liver Disease associated Pruritus, 2021- 2031F |
6.1.5 Australia Pruritus Drug Market Revenues & Volume, By Atopic Dermatitis Associated Pruritus, 2021- 2031F |
6.2 Australia Pruritus Drug Market, By Drugs |
6.2.1 Overview and Analysis |
6.2.2 Australia Pruritus Drug Market Revenues & Volume, By Corticosteroids, 2021- 2031F |
6.2.3 Australia Pruritus Drug Market Revenues & Volume, By Antihistamines, 2021- 2031F |
6.2.4 Australia Pruritus Drug Market Revenues & Volume, By Counterirritants, 2021- 2031F |
6.3 Australia Pruritus Drug Market, By Route of Administration |
6.3.1 Overview and Analysis |
6.3.2 Australia Pruritus Drug Market Revenues & Volume, By Injectable, 2021- 2031F |
6.3.3 Australia Pruritus Drug Market Revenues & Volume, By Topical, 2021- 2031F |
6.3.4 Australia Pruritus Drug Market Revenues & Volume, By Oral, 2021- 2031F |
6.4 Australia Pruritus Drug Market, By End Users |
6.4.1 Overview and Analysis |
6.4.2 Australia Pruritus Drug Market Revenues & Volume, By Hospitals, 2021- 2031F |
6.4.3 Australia Pruritus Drug Market Revenues & Volume, By Homecare, 2021- 2031F |
6.4.4 Australia Pruritus Drug Market Revenues & Volume, By Specialty Clinics, 2021- 2031F |
6.5 Australia Pruritus Drug Market, By Distribution Channel |
6.5.1 Overview and Analysis |
6.5.2 Australia Pruritus Drug Market Revenues & Volume, By Hospital Pharmacy, 2021- 2031F |
6.5.3 Australia Pruritus Drug Market Revenues & Volume, By Online Pharmacy, 2021- 2031F |
6.5.4 Australia Pruritus Drug Market Revenues & Volume, By Retailers, 2021- 2031F |
7 Australia Pruritus Drug Market Import-Export Trade Statistics |
7.1 Australia Pruritus Drug Market Export to Major Countries |
7.2 Australia Pruritus Drug Market Imports from Major Countries |
8 Australia Pruritus Drug Market Key Performance Indicators |
8.1 Number of clinical trials for pruritus drugs in Australia |
8.2 Patient satisfaction rates with pruritus drug treatments |
8.3 Adoption rate of new pruritus drug therapies in the market |
9 Australia Pruritus Drug Market - Opportunity Assessment |
9.1 Australia Pruritus Drug Market Opportunity Assessment, By Types, 2021 & 2031F |
9.2 Australia Pruritus Drug Market Opportunity Assessment, By Drugs, 2021 & 2031F |
9.3 Australia Pruritus Drug Market Opportunity Assessment, By Route of Administration, 2021 & 2031F |
9.4 Australia Pruritus Drug Market Opportunity Assessment, By End Users, 2021 & 2031F |
9.5 Australia Pruritus Drug Market Opportunity Assessment, By Distribution Channel, 2021 & 2031F |
10 Australia Pruritus Drug Market - Competitive Landscape |
10.1 Australia Pruritus Drug Market Revenue Share, By Companies, 2024 |
10.2 Australia Pruritus Drug Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |